FX.co ★ KalVista Pharma Announces Positive Results From Late-stage Study Of Sebetralstat

KalVista Pharmaceuticals, a clinical-stage pharmaceutical firm, has announced positive results from its phase 3 clinical trial regarding the drug sebetralstat. The trial showed that sebetralstat had significant efficacy as an oral on-demand therapy for hereditary angioedema (HAE).

This phase 3 trial was the most extensive and representative study conducted on HAE to date. It included a wide range of participants, including adolescents, patients using long-term prophylaxis, and individuals with varying attack severities and locations.

The trial met all primary and key secondary goals and revealed a favorable safety profile for sebetralstat. In comparison to a placebo, HAE attacks treated with both 300mg and 600mg doses of sebetralstat saw significantly faster symptom relief.

These findings are consistent with previous studies, showing that sebetralstat was well-tolerated by patients and had a safety profile similar to a placebo. During the trial, no patients had to withdraw due to adverse events and there were no serious adverse events related to the treatment.

Andrew Crockett, KalVista’s CEO, expressed excitement over the Phase 3 results for the KONFIDENT trial. According to him, these results potentially position sebetralstat as the first oral, on-demand therapy for the treatment of HAE. He asserted that the clinically meaningful results could signify a significant advancement for individuals living with HAE and, if approved, sebetralstat could provide an effective and safe oral therapy for rapid symptom relief, potentially making it an attractive treatment option for patients and caregivers.